CERo Therapeutics Holdings(CERO)
$0.00-0.00 (-10.00%)
CERO
CERo Therapeutics Holdings financials statements
$0.00
At close:-0.00 (-10.00%)
CERo Therapeutics Holdings (CERO) Ratios
500 Followers
CERo Therapeutics Holdings Ratios
CERO's free cash flow for Q3 2026 was $-3.03M. For the 2026 fiscal year, CERO's free cash flow was increased by $3.00 and operating cash flow was $-3.03M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.30 | 0.50 | 0.38 | 1.38 | 13.88 |
| Quick Ratio | 0.30 | 0.50 | 0.38 | 1.38 | 13.88 |
| Cash Ratio | 0.18 | 0.45 | 0.31 | 1.37 | 11.20 |
| Solvency Ratio | -2.07 | -0.81 | 0.00 | 0.06 | 0.05 |
| Operating Cash Flow Ratio | -1.77 | -0.78 | -1.12 | -0.04 | -7.11 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -6.61 | -3.72 | -1.68 | 0.00 |
| Net Current Asset Value | $ -6.35M | $ -4.39M | $ -45.21M | $ 2.47M | $ -7.89M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.25 | 0.30 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | -0.13 | -0.83 | -0.27 | 0.26 | 0.02 |
| Debt-to-Capital Ratio | -0.15 | -4.94 | -0.37 | 0.21 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.67 | -3.28 | -0.89 | 17.16 | 1.05 |
| Debt Service Coverage Ratio | 0.00 | -7.50 | -1.63 | -1.03 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.06 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.17 | 13.04 | 211.48 | 88.40 | 489.90 |
| Net Debt to EBITDA | 0.06 | 0.27 | 0.02 | 605.04 | 6.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 0.10% | 973.70% | 94.93% |
| EBT Per EBIT | 107.89% | 50.53% | 83.24% | 2.36% | 100.12% |
| Return on Assets (ROA) | -547.09% | -124.57% | -0.05% | -1.58% | -0.18% |
| Return on Equity (ROE) | 365.75% | 408.12% | 0.04% | -27.05% | -0.18% |
| Return on Capital Employed (ROCE) | 338.99% | 1279.92% | 6224.63% | -25.01% | -0.18% |
| Return on Invested Capital (ROIC) | 388.91% | 4795.56% | -194.51% | -17.56% | -0.17% |
| Return on Tangible Assets | -547.09% | -124.57% | -0.05% | -1.58% | -0.17% |
| Earnings Yield | -7034.28% | -53.34% | -0.00% | -0.44% | -0.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.14 | 0.26 | 0.32 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2547.83 | -1414.13 | -1154.95 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2547.83 | 1414.13 | 1154.95 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.80 | -47.93 | -787.43 | -148.54 | -94.81 |
| Free Cash Flow Per Share | -3.80 | -47.93 | -787.43 | -242.96 | -178.11 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -1929995.67 | -1.57 | -1.14 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -1929995.67 | -1.57 | -1.14 |
| Operating Cash Flow Coverage Ratio | -23.00 | -3.68 | -3.72 | -1.68 | -0.19 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -5678.29% | -39.94% | -3.58% | -1.18% | -0.90% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.00 | -17.47 | -63787.85 | -226.18 | -461.85 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.05 | -7.65 | -28.07 | 61.18 | 0.85 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.02 | -2.50 | -27.94 | -84.54 | -111.28 |
| Price-to-Operating Cash Flow Ratio | -0.02 | -2.50 | -27.94 | -138.28 | -209.06 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.18 | -5.08 | -0.37 | 0.00 |
| Enterprise Value Multiple | 0.04 | -1.94 | -66.32 | -1597.31 | 367.79 |
| Enterprise Value | -680.08K | 12.74M | 161.72M | 109.54M | 148.24M |
| EV to EBITDA | 0.04 | -1.94 | -66.32 | -1597.31 | 367.79 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.04 | -2.20 | -27.93 | -61.32 | -113.19 |
| EV to Operating Cash Flow | 0.04 | -2.20 | -27.93 | -100.29 | -212.65 |
| Tangible Book Value Per Share | -1.29 | -15.68 | -5719.80 | 335.74 | 23232.71 |
| Shareholders’ Equity Per Share | -1.29 | -15.68 | -783.74 | 335.74 | 23232.71 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.04 | -8.74 | 0.05 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -4.71 | -64.01 | -0.34 | -90.81 | -42.91 |
| Tax Burden | 1.00 | 1.00 | 0.00 | 9.74 | 0.95 |
| Interest Burden | 1.08 | 1.00 | 1.00 | 0.02 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.81 | 0.70 | 0.79 | 0.09 | 0.07 |
Currency in USD

